双歧杆菌四联活菌片联合恩替卡韦对老年乙肝肝硬化患者肝纤维化程度及IL-10、sICAM-1水平的影响  

Effects of Bifidobacterium Silian Viable Tablets and Entecavir on the Degree of Liver Fibrosis and the Levels of IL-10 and sICAM-1 in Elderly Patients with Hepatitis B Cirrhosis

作　　者：刘新德 王旭 焦成峰 LIU Xin-de;WANG Xu;JIAO Cheng-feng(Department of Infectious Disease,Joint Logistics Support Force 990th Hospital,Zhumadian 463000,Henan Province,China)

机构地区：[1]联勤保障部队第990医院感染疾病科,河南驻马店463000

出　　处：《罕少疾病杂志》2024年第8期75-77,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨双歧杆菌四联活菌片+恩替卡韦治疗老年乙肝肝硬化(hepatitis B cirrhosis,HBC)患者的效果及对肝纤维化程度、IL-10、sICAM-1水平的影响。方法选取我院2021年4月至2023月6月收治的老年HBC患者一共86例,随机分为观察组、对照组,每组43例。观察组采用双歧杆菌四联活菌片联合恩替卡韦治疗,对照组采用恩替卡韦治疗。比较2组疗效、治疗前、治疗6个月后肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)]、肝纤维化指标[层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)]、炎性因子指标[可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-10(IL-10)]水平、肠道菌群指标[乳酸杆菌、肠杆菌、双歧杆菌]数量。结果观察组总有效率高于对照组(P<0.05);治疗6个月以后观察组ALT、TBIL、AST水平均低于对照组(P<0.05);治疗6个月以后观察组LN、HA、Ⅳ-C、PCⅢ水平均低于对照组(P<0.05);治疗6个月以后sICAM-1水平低于对照组,观察组IL-10水平高于对照组(P<0.05)。结论双歧杆菌四联活菌片联合恩替卡韦治疗老年HBC患者效果确切,可有效调节肠道菌群,纠正免疫炎症反应,改善肝功能,减轻肝纤维化,利于控制病情进展。Objective To investigate the effect of Bifidobacterium Quadruple Viable Tablets and Entecavir in the treatment of elderly patients with hepatitis B B cirrhosis(HBC)and its influence on the degree of liver fibrosis,IL-10,sICAM-1 levels.Method A prospective selection was conducted on 86 elderly HBC patients admitted to our hospital from April 2021 to June 2023.They were randomly divided into an observation group and a control group using a random number table method,with 43 patients in each group.The observation group was treated with Bifidobacterium quadruplex viable tablets combined with Entecavir,and the control group was treated with Entecavir.Compare the efficacy of the two groups,before treatment,and after 6 months of treatment,liver function indicators[alanine aminotransferase(ALT),total bilirubin(TBIL),Asparagus cochinchinensis aminotransferase(AST)],liver fibrosis indicators[hyaluronic acid(HA),collagen IV(IV-C),Laminin(LN),procollagen III(PC III)],inflammatory factor indicators[soluble Intercellular adhesion molecule-1(sICAM-1),Interleukin 10(IL-10)]Gut microbiota index[Lactobacillus,Enterobacter,Bifidobacterium]number.Results The total effective rate of the observation groupwas higher than that of the control group(P<0.05);after 6 months of treatment,the levels of ALT,TBIL,and AST in the observation group were lower than those in the control group(P<0.05);after 6 months of treatment,the levels of HA,IV-C,LN,and PC III in the observation group were lower than those in the control group(P<0.05);after 6 months of treatment,the IL-10 level in the observation group was higher than that in the control group,while the sICAM-1 level was lower than that in the control group(P<0.05).Conclusion Bifidobacterium Silian Viable Tablets combined with Entecavir is effective in the treatment of elderly HBC patients.It can effectively regulate Gut microbiota,correct immune inflammatory reaction,improve liver function,alleviate liver fibrosis,and help control the progress of the disease.

关 键 词：双歧四联活菌 恩替卡韦 乙肝肝硬化 可溶性细胞间黏附分子-1 肝纤维化 

分 类 号：R512.6[医药卫生—内科学]